New study tracks how leukemia drug works outside the lab

NCT ID NCT06092879

Ongoing Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 201 adults with chronic myeloid leukemia who are taking asciminib (Scemblix) as a third or later treatment option. Researchers want to see how long patients stay on the drug and how well it controls their cancer in real-world settings. The goal is to gather practical information that goes beyond clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: asciminib (Scemblix)
What this could lead to: If successful, this study could provide real-world evidence on how well asciminib works and is tolerated in everyday practice for patients with chronic myeloid leukemia who have tried other treatments.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by patient selection and real-world variability. It does not test a new treatment but gathers data on existing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOID LEUKEMIA

Contacts and locations

Locations

Novartis Investigative Site

Angers, France, 49933, France
Novartis Investigative Site

Limoges, Haute Vienne, 87000, France
Novartis Investigative Site

Saint Priest Jarez, Pays de la Loire Region, 42270, France
Novartis Investigative Site

Aix-en-Provence, 13616, France
Novartis Investigative Site

Amiens, 80054, France
Novartis Investigative Site

Antibes, 06600, France
Novartis Investigative Site

Avignon, 84000, France
Novartis Investigative Site

Besançon, 25030, France
Novartis Investigative Site

Bobigny, 93009, France
Novartis Investigative Site

Bordeaux, 33000, France
Novartis Investigative Site

Bordeaux, 33076, France
Novartis Investigative Site

Brest, 29609, France
Novartis Investigative Site

Brive-la-Gaillarde, 19100, France
Novartis Investigative Site

Caen, 14033, France
Novartis Investigative Site

Cagnes-sur-Mer, 06800, France
Novartis Investigative Site

Cannes, 06414, France
Novartis Investigative Site

Castelnau-le-Lez, 34170, France
Novartis Investigative Site

Cesson-Sévigné, 35576, France
Novartis Investigative Site

Chambéry, 73000, France
Novartis Investigative Site

Clermont-Ferrand, 63003, France
Novartis Investigative Site

Corbeil-Essonnes, 91100, France
Novartis Investigative Site

Dunkirk, 59240, France
Novartis Investigative Site

Essey-lès-Nancy, 54270, France
Novartis Investigative Site

Grenoble, 38043, France
Novartis Investigative Site

Le Kremlin-Bicêtre, 94275, France
Novartis Investigative Site

Le Mans, 72000, France
Novartis Investigative Site

Lens, 62307, France
Novartis Investigative Site

Libourne, 33505, France
Novartis Investigative Site

Lorient, 56100, France
Novartis Investigative Site

Lyon, 69373, France
Novartis Investigative Site

Montpellier, 34070, France
Novartis Investigative Site

Montpellier, 34295, France
Novartis Investigative Site

Mulhouse, 68070, France
Novartis Investigative Site

Nantes, 44277, France
Novartis Investigative Site

Nevers, 58000, France
Novartis Investigative Site

Nîmes, 30029, France
Novartis Investigative Site

Paris, 75013, France
Novartis Investigative Site

Paris, 75015, France
Novartis Investigative Site

Paris, 75475, France
Novartis Investigative Site

Perpignan, 66046, France
Novartis Investigative Site

Pierre-Bénite, 69495, France
Novartis Investigative Site

Poitiers, 86021, France
Novartis Investigative Site

Quimper, 29000, France
Novartis Investigative Site

Rennes, 35033, France
Novartis Investigative Site

Roubaix, 59100, France
Novartis Investigative Site

Strasbourg, 67085, France
Novartis Investigative Site

Tarbes, 65100, France
Novartis Investigative Site

Toulouse, 31059, France
Novartis Investigative Site

Tours, 37044, France
Novartis Investigative Site

Valence, 26953, France
Novartis Investigative Site

Vandœuvre-lès-Nancy, 54511, France
Novartis Investigative Site

Vesoul, 70014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.